Undervalued Large-Cap Healthcare Stocks on NAS May 2025

May 20, 2025

Healthcare Sector

The healthcare sector includes companies in biotechnology, pharmaceuticals, hospitals, home and long-term care. It also includes related medical equipment manufacturers and suppliers.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Healthcare stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
SRPT Sarepta Therapeutics 37.94 76.50 101.63 4836589 3694 0.00 0.0
GMAB Genmab 19.88 38.66 94.45 1473406 12710 0.00 11.8
ACHC Acadia Healthcare Co 25.08 44.00 75.44 3175885 2308 0.00 12.3
MRNA Moderna 26.39 43.09 63.27 10111599 10187 0.00 0.0
IBRX ImmunityBio 2.84 4.24 49.34 9480673 2423 0.00 0.0
HRMY Harmony Biosciences Hldgs 35.07 50.45 43.86 710106 2052 0.00 13.7
LNTH Lantheus Holdings 78.25 109.77 40.28 1388408 5592 0.00 22.3
REGN Regeneron Pharmaceuticals 596.54 828.09 38.81 1369845 66335 0.15 15.2
GRFS Grifols 7.76 10.69 37.78 926528 5276 0.00 31.2
PCVX Vaxcyte 32.03 44.09 37.65 2109433 4346 0.00 0.0
All data provided as at market close May 18, 2025.

Company Details

Sarepta Therapeutics

SRPT:NAS

Close Price

37.94

Our Valuation

76.50

% Difference

101.63

Market Cap ($M)

3694

P/E Ratio

0.0

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates.

Access the stockcalc valuation


Genmab

GMAB:NAS

Close Price

19.88

Our Valuation

38.66

% Difference

94.45

Market Cap ($M)

12710

P/E Ratio

11.8

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product.

Access the stockcalc valuation


Acadia Healthcare Co

ACHC:NAS

Close Price

25.08

Our Valuation

44.00

% Difference

75.44

Market Cap ($M)

2308

P/E Ratio

12.3

Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.

Access the stockcalc valuation


Moderna

MRNA:NAS

Close Price

26.39

Our Valuation

43.09

% Difference

63.27

Market Cap ($M)

10187

P/E Ratio

0.0

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

ImmunityBio

IBRX:NAS

Close Price

2.84

Our Valuation

4.24

% Difference

49.34

Market Cap ($M)

2423

P/E Ratio

0.0

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies.

Access the stockcalc valuation


Harmony Biosciences Hldgs

HRMY:NAS

Close Price

35.07

Our Valuation

50.45

% Difference

43.86

Market Cap ($M)

2052

P/E Ratio

13.7

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy.

Access the stockcalc valuation


Lantheus Holdings

LNTH:NAS

Close Price

78.25

Our Valuation

109.77

% Difference

40.28

Market Cap ($M)

5592

P/E Ratio

22.3

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer.

Access the stockcalc valuation


Regeneron Pharmaceuticals

REGN:NAS

Close Price

596.54

Our Valuation

828.09

% Difference

38.81

Market Cap ($M)

66335

P/E Ratio

15.2

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis.

Access the stockcalc valuation


Grifols

GRFS:NAS

Close Price

7.76

Our Valuation

10.69

% Difference

37.78

Market Cap ($M)

5276

P/E Ratio

31.2

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value.

Access the stockcalc valuation


Vaxcyte

PCVX:NAS

Close Price

32.03

Our Valuation

44.09

% Difference

37.65

Market Cap ($M)

4346

P/E Ratio

0.0

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Sarepta Therapeutics and Genmab are the most undervalued Large-Cap Healthcare stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-large-cap-healthcare-stocks-nas-may-2025
Sarepta Therapeutics $SRPT and Genmab $GMAB are the most undervalued Healthcare stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-large-cap-healthcare-stocks-nas-may-2025
Sarepta Therapeutics and Genmab are the most undervalued Large-Cap Healthcare stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-large-cap-healthcare-stocks-nas-may-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.